^
Association details:
| Biomarker: | EGFR T790M |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study
Published date:
07/03/2020
Excerpt:
The frequency of T790M mutation at P2 was similar in both arms: 8 (19.0%) in BE and 11 (20.8%) in E...This revealed that BE was more efficacious than E, and that BE was associated with improved PFS in all types.
DOI:
10.1016/j.ebiom.2020.102861
Source:
Title:
Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study
Excerpt:
...An exon 19 deletion mutation or exon 21 L858R mutation in EGFR has been found clinically, with or without EGFR T790M mutation 5....
Source:
Title:
Efficacy study of pemetrexed/carboplatin/bevacizumab with or without combination of sincilumab in advanced non-squamous and non-small cell lung cancer with EGFR-sensitive mutations and failed EGFR-TKI therapy
Excerpt:
...3.Advanced or recurrent stage III B-C or IV non-squamous or non-small cell lung cancer confirmed by histology and/or cytology (According to the AJCC staging system, version 8) with sensitive EGFR mutations and meeting the following conditions: 1) After treatment failure with first or second-generation EGFR-TKI (Including gefitinib, erlotinib, icotinib, afatinib, etc), the patient's genetic test showed no T790M mutation in exon 20 after re-biopsy; 2) After treatment failure with first or second-generation EGFR-TKI single agent (Including gefitinib, erlotinib, icotinib, afatinib, etc), the patient's genetic test after re-biopsy developed a T790M mutation in exon 20, and then developed disease progression again after receiving osimertinib or other three-generation EGFR-TKIs; 3) Participants who had failed previous osimertinib or other three-generation EGFR-TKIs as first-line treatment met the inclusion criteria (regardless of their EGFR T790M mutation status). ...
Trial ID: